WebAbstract. Purpose To examine the effectiveness of hyperthermic intravesical chemotherapy (HIVEC™) with mitomycin-C (MMC) for patients with intermediate–high-risk non-muscle invasive bladder cancer (NMIBC).Materials and methods From November 2010 to April 2015, 40 patients with intermediate–high-risk NMIBC received HIVEC™ treatment with … Web31 aug. 2024 · Aim: This study aimed to investigate the effectiveness of electromotive drug administration (EMDA) of mitomycin C (EMDA/MMC) in intermediate- and high-risk NMIBC patients 6 months after the end of ...
Intravesical Administration of Therapeutic Medication for the …
WebBackground: Optimising therapeutic strategies of intermediate-risk non-muscle-invasive bladder cancer (IR-NMIBC) is needed. Objective: To compare recurrence-free survival … Web1 mrt. 2024 · PDF On Mar 1, 2024, D.A. González Padilla and others published HIVEC HR: Chemohyperthermia with mitomycin C vs BCG for high-risk non-muscle invasive bladder cancer. Preliminary results from a ... eclipse怎么创建java web程序
Full article: Treatment Outcomes of High-Risk Non-Muscle …
Webthat patients with intermediate-risk NMIBC should be offered a six-dose course of intravesical Mitomycin C, but these recommendations do not mention any role for … Web17 jul. 2024 · This randomized, controlled non-inferiority trial compared recurrence-free survival of two parallel groups consisting of patients with EORTC-score intermediate-risk tumours. Patients of the first group received photodynamic-assisted TURB with single-shot instillation of Mitomycin (n=67; 40 mg Mitomycin). ... Web26 sep. 2024 · Interim findings were also released for UGN-102 in patients with intermediate-risk, low-grade non muscle invasive bladder cancer (LG NMIBC) from the phase IIb OPTIMA II trial. UGN-101 in Low-Grade Upper Tract Urothelial Cancer. ... UGN-101 (mitomycin gel) ... reloj 45 min